| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Synlogic, Inc.$0.66
+0.04 (+7.27%)
D 34Pipeline Score Undervalued Biotech · Clinical
Market Cap
6.55 M
EPS
-0.27
P/E Ratio
-
Value Trade
457.25
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
49.00 K
Operating CF
-563.00 K
Total Assets
14.61 M
Total Liabilities
14.61 M
Equity
12.55 M
-50.88 %
Week
-52.14 %
1 Month
-67.91 %
3 Month
-65.54 %
6 Month
-99.03 %
5 Year
-99.93 %
All Time
Cash Data
Cash Position
14.11 M
Monthly Burn
188.00 K
Runway
72.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
748.00
52 Week Range
0.56 - 1.96
% held by Insiders
39.35 %
% held by Institutions
37.16 %
Enterprise Value
-9.04 M
Total Shares
11.71 M
Short %
0.46 %
Float Shares
7.04 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D34
Pipeline Score $24M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored3.7x
rNPV / MCap Top 46%
Micro Cap (rank 499 of 923)
Percentile RankSynlogic, Inc. faces pipeline headwinds (34/100), with $325M risk-adjusted pipeline value, led by SYNB1934 in Healthy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNB1934 Small molecule | Healthy | Phase 1 | NCT04984525 | 16% | $106M | COMPLETED | 106 | - | - | Dec 10, 2021 | - | May 18, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SYNB8802 | Enteric Hyperoxaluria | Phase 1b | 2022-12-15 | -38% reduction in urinary oxalate compared to placebo; -28% (-37.2, -18.2) change from baseline in urinary oxalate vs. placebo at the 1x1011 TID dose; -38% (-46.4, -28.7) change from baseline in urinary oxalate vs. placebo at the 3x1011 TID dose Read More | Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study Results include -38% reduction in urinary oxalate compared to placebo in Roux-e Read More | |
SYNB8802 | Enteric Hyperoxaluria | Phase 1b | 2022-12-15 | -38% reduction in urinary oxalate compared to placebo; -28% (-37.2, -18.2) change from baseline in urinary oxalate vs. placebo at the 1x1011 TID dose; -38% (-46.4, -28.7) change from baseline in urinary oxalate vs. placebo at the 3x1011 TID dose Read More | Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study Results include -38% reduction in urinary oxalate compared to placebo in Roux-e Read More | |
SYNB8802 | Enteric Hyperoxaluria | Phase 1b | 2022-12-15 | -38% reduction in urinary oxalate compared to placebo; -28% (-37.2, -18.2) change from baseline in urinary oxalate vs. placebo at the 1x1011 TID dose; -38% (-46.4, -28.7) change from baseline in urinary oxalate vs. placebo at the 3x1011 TID dose Read More | Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study Results include -38% reduction in urinary oxalate compared to placebo in Roux-e Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SYBX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SYBX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SYBX ranks across every disease it competes inCompetitive Position is a premium feature
See how SYBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial